There's never a sure thing when it comes to decisions from the Food and Drug Administration, but when it comes to Cornerstone Therapeutics' (UNKNOWN:CRTX.DL) drug Lixivaptan, investors have all but conceded that a complete response letter (read: rejection) is in the cards.

In the following video, health care bureau chief Brenton Flynn and analyst David Williamson discuss why the outlook is so gloomy for this drug, and how one company is looking particularly smart for cutting ties with the drug two years ago.

Brenton Flynn and David Williamson have no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Biogen Idec. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.